US FDA To Explore New Regulatory Pathways For Some Cellular Products

 
• By Sue Sutter
  
Peter Marks with cellular background
CBER Director Peter Marks says FDA plans to explore whether there is an intermediate pathway between tissue regulations and a full BLA for certain cellular products. • Source: Nielsen Hobbs; the Pink Sheet | Shutterstock, Getty images

More from Cell & Gene Therapies

More from Advanced Technologies